Acousia Therapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.acousia.com
ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin
Phase 2
Recruiting
- Conditions
- Cisplatin-induced Hearing Loss
- Interventions
- Drug: ACOU085 (bimokalner)Drug: Placebo
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Acousia Therapeutics GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT06521190
- Locations
- 🇩🇪
Dept. of Otolaryngology - Head and Neck Surgery, Tuebingen University, Tuebingen, Baden-Wuerttemberg, Germany
🇩🇪Dept. of Otolaryngology - Head and Neck Surgery, Dresden University, Dresden, Germany
🇩🇪Dept. of Otolaryngology - Head and Neck Surgery, Essen University, Essen, Germany
© Copyright 2025. All Rights Reserved by MedPath